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Failure to extinguish fear and genetic variability in the
human cannabinoid receptor 1
I Heitland1,2, F Klumpers1,2, RS Oosting3, DJJ Evers1, J Leon Kenemans1,2 and JMP Baas1,2
Failure to extinguish fear can lead to persevering anxiety and has been postulated as an important mechanism in the
pathogenesis of human anxiety disorders. In animals, it is well documented that the endogenous cannabinoid system has a
pivotal role in the successful extinction of fear, most importantly through the cannabinoid receptor 1. However, no human
studies have reported a translation of this preclinical evidence yet. Healthy medication-free human subjects (N¼ 150)
underwent a fear conditioning and extinction procedure in a virtual reality environment. Fear potentiation of the eyeblink startle
reflex was measured to assess fear-conditioned responding, and subjective fear ratings were collected. Participants were
genotyped for two polymorphisms located within the promoter region (rs2180619) and the coding region (rs1049353) of
cannabinoid receptor 1. As predicted from the preclinical literature, acquisition and expression of conditioned fear did not differ
between genotypes. Crucially, whereas both homozygote (G/G, N¼ 23) and heterozygote (A/G, N¼ 68) G-allele carriers of
rs2180619 displayed robust extinction of fear, extinction of fear-potentiated startle was absent in A/A homozygotes (N¼ 51).
Additionally, this resistance to extinguish fear left A/A carriers of rs2180619 with significantly higher levels of fear-potentiated
startle at the end of the extinction training. No effects of rs1049353 genotype were observed regarding fear acquisition and
extinction. These results suggest for the first time involvement of the human endocannabinoid system in fear extinction.
Implications are that genetic variability in this system may underlie individual differences in anxiety, rendering cannabinoid
receptor 1 a potential target for novel pharmacological treatments of anxiety disorders.
Translational Psychiatry (2012) 2, e162; doi:10.1038/tp.2012.90; published online 25 September 2012
Introduction
From an evolutionary perspective, the acquisition of fear
responses enables organisms to respond appropriately to
predictors of aversive events.1,2 Yet, it is equally important to
extinguish fear when cues that previously predicted danger
are no longer followed by an aversive event.3 Failure to do so
can lead to persevering fear and has been postulated as an
important mechanism in the pathogenesis of human anxiety
disorders.4,5 Exposure-based psychotherapy aims to counter-
act the previously acquired conditioned fear responses by
repeatedly presenting the learned predictor of the aversive
event (conditioned stimulus, CS) in absence of its negative
consequences.3,4,6 A better understanding of the factors that
impede fear extinction is likely to increase the efficacy of
therapy for anxiety disorders and could also stimulate the
development of new treatments.7
Several neurotransmitter systems that constitute targets
for the pharmacological facilitation of fear extinction have
been proposed recently.3,4,6,8 One of these is the endogen-
ous cannabinoid system (ECS). A vast amount of research
has been conducted in animals, where the pivotal role of
the ECS in the extinction of fear is well documented
(see Lafeneˆtre et al.9 for a review). These effects have
been shown for both cue-specific conditioned responses
(suggested to model phobic fear10,11) as well as context-
conditioned responses (suggested to model more diffuse
anxiety10,12). Most actions of cannabinoids in the central
nervous system are mediated by cannabinoid receptor 1
(CB1), one of the most abundant G-protein-coupled recep-
tors in the mammalian brain.13–15 CB1 is highly expressed in
brain regions essential for fear processing, such as the
amygdala, the hippocampus and the medial prefrontal
cortex.16–19 In rodents, it has been shown that both genetic
deletion and pharmacological blockade of CB1 prevent the
successful extinction of fear,20 whereas enhancing canna-
binoid neurotransmission by anandamide reuptake inhibi-
tors11,21 or a direct CB1 agonist22 augments fear extinction.
Given the vast amount of preclinical evidence, cannabinoid-
based pharmacotherapy in humans has been proposed
frequently as a promising avenue for the development of new
treatments for anxiety.6,23–26 However, there is as of yet a
great paucity in research regarding mechanisms through
which the ECS may regulate fear states in humans, such as
through fear extinction. This impedes utilization of the ECS in
development of novel human treatments. Narrowing the gap
between preclinical and human studies is therefore highly
desirable and could enable novel pharmacological applica-
tions that exploit the ECS.
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In anxiety research, an established tool for the assessment
of fear-conditioned responses is fear potentiation of the
startle reflex (FPS). It serves as a physiological index
of the defensive state of an organism evoked by threat,27–32
and is widely used in both animal and human research
on cue-specific fear and contextual anxiety.27,29 This includes
preclinical studies on the role of CB1,11,33 rendering it an
excellent tool for translational research.27,34 Thus far,
however, only a single published study investigated the
role of cannabinoids in human fear extinction.35 In this
study, the CB1 agonist D9-THC was administered before
extinction that followed a classical fear conditioning proce-
dure, but no long-lasting effects on fear extinction were
observed. This may be due to relatively little room for
improvement of this process in healthy human subjects, as
observed with studies on augmentation of extinction in
conditioning paradigms vs patients using D-cycloserine.35–38
Also, the lack of selective CB1 (ant)agonists available for use
in humans may underlie the paucity of human pharmacolo-
gical studies.
An alternative to the pharmacological approach is to study
the effects of genetic variability in human endocannabinoid
signaling, in analogy to the animal work with knock-out
mice.20,39,40 This is a potentially fruitful approach as anxiety
disorders show strong heritability,41 and evidence indicates
that both fear acquisition42 and fear extinction43 are modu-
lated by genetic factors (see Lonsdorf and Kalisch44 for an
overview). Many polymorphic sites have been identified
within the human gene that encodes for cannabinoid
receptor 1 (ref. 45) (often referred to as CNR1). Conse-
quences at the molecular level have not been determined for
most of these polymorphisms, however functional signifi-
cance is suggested by studies in which significant associa-
tions with a behavioral phenotype were reported.
For this study, two single-nucleotide polymorphisms (SNP)
that have been associated with individual differences in
anxiety were selected as candidates. The first SNP within
the promoter region of CNR1, rs2180619,16 was associated
with individual differences in trait anxiety in healthy humans in
interaction with the 5-HTTLPR polymorphism.46 In silico
analysis suggest possible phenotypic effects of rs2180619
through allele-specific transcription factor-binding sites46 and
its location within a regulatory region of CNR1.16 A second
SNP located within the coding region of CB1, rs1049353, was
associated with post-traumatic stress disorder as part of a
CB1 haplotype.47 Moreover, this SNP was associated with
reduced anti-depressant treatment response in subjects with
major depressive disorder, particularly in females with high
comorbid anxiety.48
In sum, the aim of this paper is to investigate if
preclinical evidence regarding the involvement of CB1 in fear
extinction can be translated to humans. To this end, 150
healthy human subjects (90 women, 60 men) were subjected
to a well-established fear conditioning and extinction para-
digm49,50 in a virtual reality environment in which both cue-
specific and contextual conditioned responses were
assessed. Eyeblink startle reflex was recorded as physiolo-
gical index of defensive state, and subjective fear ratings were
gathered at regular intervals during the experiment. To assess
possible effects of the ECS on these processes, subjects were
genotyped for the selected CNR1 SNPs (rs2180619 and
rs1049353).
Materials and methods
The ethical institutional review board of the University Medical
Center Utrecht approved this study, and all subjects gave
written informed consent.
Participants. A total of 150 subjects (90 females, 60 males;
mean age¼ 21.6, s.d.¼ 2.4) were recruited via advertise-
ments at Utrecht University. Participants filled out screening
forms in which they reported to be free of any current or
previous psychiatric or neurological disorder, drug or alcohol
dependence, current psychoactive medication, hearing pro-
blems and color blindness. Of the 150 subjects, 148 were of
Caucasian ethnicity, the remaining 2 reported to be of Asian
ancestry. Participants received h 30 for their participation in
the experiment. Eight subjects were excluded from the final
sample owing to incomplete recordings of startle data (n¼ 4),
artifacts yielding unreliable startle measurements (n¼ 2) and
insufficient quality of isolated DNA (n¼ 2). The final sample
therefore comprised 142 subjects between 18 and 28 years
of age (84 females, 58 males; mean age¼ 21.7, s.d¼ 2.4).
Experimental paradigm. All subjects completed a well-
established fear-potentiated startle (FPS)-conditioning para-
digm in a virtual reality environment adapted from Baas
et al.49–51 to assess fear extinction. Subjects were presented
with two virtual environments. These were an apartment in a
high-rise in a downtown area and a house in a suburban
area. For each subject, one of the contexts was defined as
the threat context where shocks were administered (CXTþ ),
whereas the other represented the safe context without
shock reinforcement (CXT ). Assignment of the threat
context and order of visits to the contexts was counter-
balanced across subjects. Similar to animal studies,20 an
increase in background illumination (light on, 8 s duration)
signaled when shocks could be administered in the threat
context. Light-on presentations in the safe context were
never followed by shock and were originally implemented to
assess generalization of fear. As this phenomenon
was not the focus of the present study and as there was no
significant effect of CB1 genotype on fear generalization in
any phase of the experiment, data from this condition will be
omitted for sake of brevity. Pictures from both contexts
during light off and light on as well as procedural details of
this paradigm can be found elsewhere.50,51 Subjects were
presented with the virtual environments in blocks lasting
5.25min during which both contexts were visited. The
beginning of each block and transitions between contexts
consisted of virtual transits through a metro station during
which startle probes were presented to maintain startle
habituation.50,51
The experiment was divided into three phases (see Figure 1
for an illustration). The paradigm started with six uninstructed
acquisition blocks to assess the development of contingency
awareness (uninstructed acquisition). During this phase,
training blocks with a relatively high reinforcement rate of
75% to facilitate learning were alternated with testing blocks.
Relatively low reinforcement rates in testing blocks
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(37.5%) prevented contamination of the assessment of
physiological responding due to shock sensitization (see also
Baas et al.50,51). The uninstructed acquisition phase was
followed by explicit verbal and written instructions about the
contingency between threat context, threat cue and shock
reinforcements to ensure contingency learning in all partici-
pants. These instructions were followed by one training block
to reinforce the instructions and four testing blocks to assess
instructed fear acquisition. The primary focus of this study was
to investigate CB1/CNR1 effects on fear extinction. Analyses
of CB1/CNR1 genotype effects during acquisition are reported
succinctly to rule out confounds due to possible differences
before the extinction phase. Note, that the fear acquisition
phase was split up into uninstructed and instructed acquisition
to investigate the effect of individual differences on the
spontaneous acquisition of cue-dependent and context-
dependent fear (not the topic of this manuscript), while
ensuring fear learning for all subjects by means of explicit
instructions. This approach allows for strong and homoge-
neous fear acquisition against which extinction can be tested
robustly.
Immediately following the instructed acquisition phase,
without an additional pause or additional instructions, the
extinction phase followed comprising four more blocks that
were identical to the blocks used during acquisition but without
shock reinforcements.
For analyses purposes, the extinction phase was divided
into early extinction (first two extinction blocks) and late
extinction (last two extinction blocks). These were compared
with the last two blocks of the acquisition phase (referred to as
late acquisition). This way, data from the three phases that
were used to measure fear extinction (late acquisition, early
extinction, late extinction) contain an identical number of
blocks. An illustration of the experimental design is provided in
Figure 1.
Throughout the experiment, startle probes were presented
during three out of four light-on presentations in both contexts.
In addition, three startles probes were presented in absence
of the light cue in each context. These are further referred to
as the light-off condition. As a result, each block contained
three startles measurements per condition (light-on/CXTþ ;
light-off/CXTþ ; light-on/CXT (omitted for sake of brevity,
see above); light-off/CXT ). To increase signal-to-noise
ratio, startle data from two subsequent testing blocks were
averaged, resulting in an average computed across six
startles per condition for final analyses.
Shock administration and workup. Electrical shocks were
administered with a constant current generator (Digitimer
DS7A, Digitimer, Letchworth Garden City, UK) via tin cup
electrodes located approximately over the medial nerve on
the inner left wrist. Before the experiment started, subjects
completed a shock workup to determine individual shock
intensities as described elsewhere.52,53 Intensities were
adjusted per subject so that they corresponded to a level of
4 out of 5, representing ‘quite annoying/ painful’.
Startle probe presentation, data recording and proces-
sing. Recording and amplification of the eyeblink startle
reflex was performed via electromyography of the right
orbicularis oculi muscle using a Biosemi ActiveTwo system
(BioSemi Instrumentation, Amsterdam, The Netherlands).
Startle probes comprised 50-ms, 105-dB white-noise bursts
with instantaneous rise time and were delivered through
headphones (Sennheiser Electronic HD202, Wennebostel,
Germany). Processing of startle data was performed using
Brain Vision Analyzer software (Brain Products, Gilching,
Germany) according to published guidelines54 and previous
studies.52,53 After segmentation of trials, artifacts were
rejected and null responses identified as in previous
publications.52,53,55 Participants were only included in the
final analysis if at least one artifact-free startle trial for each
condition and each phase was recorded. Two participants
were excluded from the analyses due to not meeting this
criterion. According to guidelines, startle data were Z-
transformed per subject based on individual trial amplitudes
from all startles recorded during the experiment to remove
between-subjects variance in baseline startle amplitude.
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Figure 1 (a) Outline of the design of the virtual reality fear conditioning/extinction task delineating number of blocks and reinforcement rates per experimental
phase. (b) An example of the composition of a single acquisition block of the virtual reality fear conditioning task is given. During extinction blocks, no shocks
were administered. Note that reinforcement rates were 37.5% within the acquisition blocks during which physiological data was recorded. The blocks with a reinforcement
rate of 75% were included to ensure learning. Physiological data from these blocks were omitted during analyses as shock administration contaminates startle
measurements.49,50
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All statistical analyses involving startle data were conducted
on Z-scores.
Subjective measures. Before the experiment, subjects
filled out Spielberger’s Trait Anxiety Inventory (Dutch
translation,56) and the neuroticism subscale of the NEO-PI-
R questionnaire (Dutch translation,57). Between blocks,
subjects rated their subjective fearfulness during the experi-
mental conditions on a visual analog scale displayed
on the computer screen while seeing screenshots from
the pre-recorded videos representative for each condition.
See Baas et al.50 for examples of screenshots. The question
was ‘How fearful do you feel in this situation?’ with the
anchors: ‘Not at all fearful of shock’ (0) and ‘Very fearful of
shock’ (100). Two screenshots per condition were presented
after each block, and an average was computed. Further
analysis of the data was congruent to our approach of the
startle data.
Genotyping. DNA was harvested by collecting buccal
swaps frozen immediately at  40 1C for later genotyping.
Genomic DNA was extracted and purified using a QIAamp
DNA Mini Kit (Qiagen, Hilden, Germany). rs2180619 and
rs1049353 were genotyped using Taqman SNP Genotyping
assays (ASSAY ID’s: C__15841551_10 and
C___1652590_10, respectively, Applied Biosystems, Foster
City, CA, USA). Subjects were classified through endpoint
analysis performed on an ABI Prism 7000 (Applied Biosys-
tems) as either A/A homozygotes, A/G heterozygotes or G/G
homozygotes. In contrast to the original studies on
rs218061946 and rs104935347,48 that did not use a priori
grouping of genotypes, we here collapsed the smallest
homozygote group of each polymorphism with the hetero-
zygotes to maximize statistical power, as is common in the
field (see Lonsdorf and Kalisch44 for an overview of genetic
association studies on human fear conditioning and extinc-
tion). For rs2180619, G-allele carriers were grouped against
A/A homozygotes, and for rs1049353, A-allele carriers were
grouped against G/G homozygotes. Genotyping was per-
formed in duplicate for B80% of the samples without
deviations. Descriptive statistics of both CB1/CNR1 poly-
morphisms are presented in Table 1. We did not perform
gene  gene interaction analysis as minimal cell sizes did
not exceed n¼ 30, thus insufficient for calculation of gene 
gene interaction effects according to statistical guidelines.58
Statistical analyses. Because of our a priori hypotheses
and for clarity, planned comparisons rather than a full
factorial design are reported. Absolute potentiation of the
startle reflex (light-on/CXTþ vs light-off/CXT ) was used
as our primary outcome measure because animal literature
has shown that CB1 exerts its effects on fear extinction of
both cue-specific fear11,20 and contextual responses.21,22
Subsequently, in case of a significant CB1 effect on this
summed score, additional analyses were performed to
determine if CB1 modulates cue-dependent fear extinction
and context-dependent fear extinction specifically.
The repeated measures ANOVA for total fear (cue and
context summed) included within-subject factors condition
(contrast: light-on/CXTþ vs light-off/CXT ) and phase (last
acquisition vs late extinction). CNR1 genotypes were included
as between-subjects’ factors with two levels (A/A homozy-
gotes vs G-allele carriers for rs2180619, and G/G homo-
zygotes vs A-allele carriers for rs1049353). In case of
significant CB1/CNR1 genotype  fear extinction interactions
for the summed cue and context measure, three sets of follow-
up tests were conducted. First, we tested whether there was a
significant reduction of fear responding within both genotype
groups separately. Second, between-genotypes differences
in fear responding at the end of extinction were assessed to
ascertain a statistically significant difference in remaining fear
responding at the end of the extinction phase between
genotypes. Finally, genotype differences in extinction were
tested separately for cue-specific responses (contrast: light-
on/CXTþ vs light-off/CXTþ ) and context-conditioned
responses (contrast: light-off/CXTþ vs light-off/CXT ) to
assess if one of the two domains was affected specifically.
Sex and age were included as covariates in the analyses to
account for possible confounding effects (statistical test
outcomes were identical with and without inclusion of
covariates).
Results
Genetics and descriptive statistics. Both polymorphisms
under study were in Hardy–Weinberg equilibrium and in
linkage equilibrium (see Table 1). Furthermore, sex was
evenly distributed across rs2180619 genotypes but unevenly
distributed across rs1049353 genotypes (see Table 1 for
frequencies and statistics). We compared the CNR1 geno-
types with regard to trait anxiety, neuroticism, shock
intensities and baseline startle amplitude, which did not
reveal significant differences (see Table 2). Hence, CNR1
genotype groups did not differ on parameters that may be
regarded as potential confounds in the fear conditioning/
extinction task, such as personality or basic defensive
response levels.
Startle results—fear acquisition. During both the un-
instructed acquisition phase and after the instructions,
Table 1 Frequencies and statistics (Hardy–Weinberg equilibrium, linkage equilibrium and sex distribution) of the genetic polymorphisms under study
Polymorphism Hardy–Weinberg
equilibrium P-value
Lowest linkage
equilibrium P-value
N’s % females x2 (gender  genotype) P (gender  genotype)
rs2180619 0.97 0.38 G/G A/G A/A G/G A/G A/A o1 0.60
23 68 51 52% 63% 57%
rs1049353 0.19 0.38 G/G A/G A/A G/G A/G A/A 6.3 0.04
73 53 16 49% 68% 75%
Human fear extinction and cannabinoid receptor 1
I Heitland et al
4
Translational Psychiatry
significant potentiation of the eyeblink startle reflex (FPS)
was observed (contrast: light-on/CXTþ vs light-off/CXT ;
uninstructed acquisition: F1,141¼ 158, Po0.001, Z2¼ 0.51;
instructed acquisition: F1,141¼ 488, Po0.001, Z2¼ 0.77). To
rule out the possibility that CB1/CNR1-dependent differences
during the acquisition phases confound later differences
during fear extinction, we tested if genetic variability in the
polymorphisms under study was associated with FPS during
both uninstructed acquisition and instructed acquisition. In
both phases, FPS was unrelated to rs2180619 and
rs1049353 genotype (F’so1). We used FPS data of the last
two blocks of the acquisition phase (further on called ‘late
acquisition’) as a baseline to evaluate the magnitude of fear
extinction (see Materials and Methods for rationale). The
robust FPS effect in these blocks (F1,141¼ 402, Po0.001,
Z2¼ 0.74) was again independent of rs2180619 and
rs1049353 genotype (F’so1).
Startle results—fear extinction. The extinction phase
followed acquisition without instructions or an additional
pause. Fear extinction, defined as decrease of FPS from the
late acquisition to late extinction (the last two blocks of
extinction), was strongly modulated by rs2180619 genotype
(late acquisition FPS vs late extinction FPS  rs2180619
genotype (A/A vs G-carriers); F1,138¼ 14.3, Po0.001,
Z2¼ 0.09, Figures 2a and c). Notably, post-hoc tests
revealed that A/A homozygotes of rs2180619 differed
significantly from both G/G homozygotes (P¼ 0.003) and
A/G heterozygotes (P¼ 0.001) with regard to fear extinction
(late acquisition FPS vs late extinction FPS), whereas G/G
homozygotes and A/G heterozygotes did not differ from
each other (P¼ 0.60). Follow-up tests revealed that the
extinction procedure did not result in reduction of FPS in the
group of 51 A/A carriers (F1,50o1), whereas G-allele
carriers of rs2180619 displayed robust extinction of fear
(F1,90¼ 43.9, Po0.001, Z2¼ 0.33). Crucially, failure to
extinguish fear resulted in significantly higher levels of
FPS for A/A homozygotes compared with G-allele carriers
at the end of extinction (F1,138¼ 10.6, P¼ 0.001, Z2¼ 0.07).
Note, that the three genotype groups are displayed
separately in Figure 2 to illustrate the data as per subgroup
for sake of completeness, whereas the respective G-carrier
vs A/A data is displayed in Supplementary Figure 1.
There were no significant effects of the other CB1/CNR1
polymorphism (rs1049353) on fear extinction as measured by
decrease of FPS from acquisition to late extinction (Fo1) or
higher levels of FPS at the end of extinction (Fo1). Note, that
different grouping of the rs1039353 genotypes (A/A vs
G-carriers) did not change the results. Therefore, no follow-
up tests were performed for rs1049353.
Cue/context-specific startle results. As planned, signifi-
cant genotype effects on summed potentiation of the startle
reflex (light-on/CXTþ vs light-off/CXT ) were followed up
by testing if these effects were specifically dependent on
differences in potentiation to the threat cue or the threat
context. During late acquisition, there was significant
potentiation to the threat cue (cue FPS: F1,141¼ 182,
Po0.001, Z2¼ 0.56) as measured by contrasting startles
during light-on/CXTþ compared with light-off/CXTþ . In
addition, there was significant potentiation to the threat
context defined as light-off/CXTþ vs light-off/CXT (con-
text FPS: F1,141¼ 88, Po0.001, Z2¼ 0.38). Both cue and
context FPS were independent of rs2180619 genotype
during all phases of acquisition (F ’so1). There was
significant reduction from late acquisition to late extinction
of potentiation to the threat cue (cue FPS: F1,141¼ 6.9,
P¼ 0.009, Z2¼ 0.05) and the threat context (context FPS:
F1,141¼ 4.2, P¼ 0.04, Z2¼ 0.03). This reduction was sig-
nificantly modulated by rs2180619 genotype regarding the
threat cue (cue FPS: F1,138¼ 4.79, P¼ 0.03, Z2¼ 0.03) and
marginally significant for the threat context (context FPS:
F1,138¼ 3.1, P¼ 0.08, Z2¼ 0.02). See Figure 2a for the time
courses and Supplementary Figures 2 and 3 for the
magnitude of extinction of cue and context FPS separately.
Failure to extinguish fear resulted in significantly higher cued
FPS (F1,138¼ 4.80, P¼ 0.03, Z2¼ 0.03) and contextual FPS
(F1,138¼ 4.85, P¼ 0.03, Z2¼ 0.03) in A/A homozygotes
compared with G-allele carriers at the end of extinction.
Subjective fear ratings. During the acquisition phase,
significant potentiation of subjective fear ratings (light-on/
Table 2 Descriptive statistics
rs2180619 rs1049353Measurement
Genotype M s.d. Statistics Genotype M s.d. Statistics
STAI-T G/G 36.83 8.85 Fo1 G/G 35.58 8.57 Fo1
A/G 35.99 8.45 A/G 36.73 8.17
A/A 35.63 6.99 A/A 36.56 6.25
NEO neuroticism G/G 132.90 24.80 Fo1 G/G 130.20 22.77 Fo1
A/G 133.30 22.40 A/G 134.27 23.05
A/A 130.50 21.90 A/A 132.31 15.94
Baseline startle amplitude (mV) G/G 96.46 72.41 Fo1.1 G/G 91.10 42.07 Fo1
A/G 79.88 50.51 A/G 88.21 60.55
A/A 94.01 62.95 A/A 86.07 61.70
Final shock intensity (mA) G/G 1.62 0.66 Fo1.4 G/G 1.79 0.87 Fo1
A/G 1.70 0.88 A/G 1.82 0.97
A/A 1.93 0.99 A/A 1.48 0.69
Means and s.d. for trait anxiety score, neuroticism, baseline startle amplitude and shock intensity reported as a function of rs2180619 and rs1049353. Statistics are
reported for the comparison between A/A homozygotes and G-allele carriers of rs2180619, and G/G homozygotes vs A-allele carriers of rs1049353.
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CXTþ vs light-off/CXT ) was observed (uninstructed
acquisition: F1,141¼ 302, Po0.001, Z2¼ 0.68; instructed
acquisition: F1,141¼ 488, Po0.001, Z2¼ 0.78; late acquisi-
tion: F1,141¼ 456, Po0.001, Z2¼ 0.76), which was unrelated
to rs2180619 and rs1049353 genotype (F’so1.3). On
average, subjects showed significant extinction of threat-
potentiated subjective fear (F1,141¼ 78, Po0.001, Z2¼ 0.36).
However, no significant effects of rs2180619 or rs1049353
genotype on fear extinction of threat-potentiated subjective
fear were observed (F’so1; Figures 2b and d). As in the
startle data, A/A homozygotes of rs2180619 showed higher
threat-potentiated subjective fear at the end of extinction, but
these differences did not reach significance (F1,138¼ 2.0,
P¼ 0.16). Furthermore, no statistically significant effects of
the genetic polymorphisms under study on cue-specific or
context-specific potentiation of subjective fear ratings were
observed.
Discussion
In this study, we tested if genetic variability in the human
cannabinoid receptor 1 is associated with the extinction of
fear. This hypothesis was directly derived from preclinical
studies,11,20 where converging evidence demonstrates CB1
as a major determinant of fear extinction (see Lafeneˆtre et al.9
for a review). To translate these findings to humans, healthy
subjects (N¼ 150) were conditioned using threat of electrical
shock in a virtual reality environment and subsequently
underwent an extinction procedure. Fear-conditioned
responses were measured by potentiation of the eyeblink
startle reflex, which serves as an objective index of basic
defensive states.27,29,32 In addition, subjects rated their
subjective fearfulness during the task.
The present data indicate that genetic variability in
rs2180619, a SNP located in the promoter region of CB1, is
strongly associated with the extinction of fear in humans.
This translates previous animal work into the human
realm for the first time. While G-allele carriers of rs2180619
(N¼ 91) displayed robust reductions of basic defensive state
during the course of extinction, such a reduction was
completely absent in A/A homozygotes (N¼ 51), which is
particularly noteworthy given this group size and the fact that
participants were selected owing to self-reported mental
health. Moreover, this effect was accompanied by higher
levels of FPS at the end of the extinction procedure in A/A
homozygotes. Of note, both rs2180619 genotype groups
showed solid and indifferent fear-conditioned responding
during the acquisition phase and during baseline startle
measurements that preceded the experimental paradigm.
This suggests that differences in fear extinction can be
ascribed to extinction rather than differences that were
present during acquisition of fear.
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Figure 2 Extinction of fear-potentiated startle (FPS) is dependent on allelic variation in the human cannabinoid receptor 1 gene. Subjects were classified as G/G
(N¼ 23), A/G (N¼ 68) or A/A (N¼ 51) allele carriers of rs2180619. Note that for purpose of statistical testing, A/A homozygotes were grouped against G-allele carriers to
assure sufficient group sizes. Top. Fear conditioning and extinction data of the startle reflex (a) and of subjective fear ratings (b). White squares denote fear potentiation to the
light cue (light on) in the threat context (CXTþ ), black circles reflect potentiation during the threat context (CXTþ ) in absence of the light cue (light off). Both potentiation
measures were computed relative to the absence of the light cue in the safe context (light-off/CXT ). Bottom. Magnitude of extinction defined as reduction of FPS
(c) and threat-potentiated fearfulness (d) for the contrast light-on/CXTþ vs light-off/CXT from late acquisition to late extinction. Greater values indicate stronger fear
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These findings suggest central human endocannabinoid
signaling as an important factor in regulation of the basic
defensive state when previously acquired fear is no longer
adaptive. Moreover, our results demonstrate that after
exposure to threat, CNR1-dependent deficits in fear regula-
tion as observed in A/A homozygotes of rs2180619 may lead
to both sustained cue-specific and context-specific fear.
Deficient fear extinction has been suggested to model a
mechanism towards clinical anxiety59 and may hence
constitute a risk factor for the development of anxiety
disorders.5,6,60 During life, every individual is inevitably
exposed to a variety of adverse events, ranging from simple
everyday stressors to traumatic experiences. Extinguishing
fear associations once they no longer lead to the expected
negative consequences hereby serves as a crucial mechan-
ism to adapt to the environment.3,60 Even though our subjects
were selected for good mental health, the insufficient
extinction of fear in A/A carriers of rs2180619 might
predispose individuals with this particular genetic CB1/
CNR1 makeup to develop anxiety disorders.
We did not find a significant association between rs1049353
located in the coding region of the CB1 gene and fear
extinction. Detailed studies on the molecular pathways by
which the candidate SNPs in this study affect CB1 functioning
are currently lacking, which complicates the interpretation of
our findings. Additional research on the molecular pathways
by which genetic polymorphisms in CB1/CNR1 affect receptor
functioning is thus warranted.
Neuropharmacologically, cannabinoids have a major reg-
ulatory role for neurotransmitters important in anxiety such as
GABA, glutamate and serotonin.61,62 Recently, several
theoretical frameworks based on preclinical work have been
published6,9,19 that posit how this may affect fear and anxiety.
A working hypothesis9 describes CB1 effects on fear
extinction as a process centered on the amygdala that
modulates both associative and non-associative (that is,
habituation-like) learning processes. During acquisition,
coupling of the conditioned stimulus (CS) and the uncondi-
tioned stimulus (US) potentiates fear circuits, resulting in a
fear-conditioned response (the ‘fear pathway’). During extinc-
tion, presentation of the CS in absence of the US leads to
activation of a ‘no-fear pathway’. This means that a new
inhibitory association is formed between the CS and the lack
of the US that competes with activation of the fear pathway for
control over behavior.4,8 Concurrently, non-associative pro-
cesses occur that decrease the organisms’ general fear state
when the US no longer is presented.8,63 According to
Lafeneˆtre et al.,9 the ECS acts on both these processes.
First, the ECS inhibits GABAergic neurotransmission during
extinction, resulting in disinhibition of the ‘no-fear pathway’
and facilitation of the new associative learning component
formed during extinction. Second, retrograde activation of the
ECS onto glutamatergic neurons leads to decreased gluta-
matergic neurotransmission, therefore contributing to the
depotentiation of the fear pathway (often called ‘habituation’
or non-associative learning). Notably, recent studies support
this view by showing that CB1-dependent neurotransmission
modulates within session extinction.64
In contrast to our startle results, subjective ratings of fear
during extinction were not significantly modulated by CB1
genotype. Absence of an effect on subjective ratings while
startle potentiation does differentiate has been reported
earlier, and various factors might contribute to a reduced
sensitivity of subjective measures, including individual differ-
ences in the interpretation of questionnaires, intentional
distortion and demand characteristics (for example, see
Hermans et al.,7 Lonsdorf et al.65 and Schinka et al.66).
Furthermore, explicit knowledge about the CS–US contin-
gencies and corresponding subjective states may not be so
dynamically altered by adaptation in limbic structures that
regulate defensive responding, such as the amygdala. In all,
subjective ratings might not be as sensitive to differences in
CB1/CNR1 as physiological data.
The present study was based on the assumption that the
genetic polymorphisms under study modulate CB1 expres-
sion. On this assumption, the present findings implicate
cannabinergic neurotransmission in human fear extinction,
thereby pointing towards a potential new target for treatment
of anxiety disorders. Because both the preclinical literature
and our findings explicitly suggest an interaction between the
cannabinoid system and extinction training, CB1 compounds
may be applicable as augmentation of exposure therapy,
similar to D-cycloserine, the partial agonist at the glycine
recognition site of the glutamatergic N-methyl-D-aspartate
receptor.67 However, recent studies demonstrated anxiolytic
effects of cannabinoid compounds, such as cannabidiol68,69
or nabilone70 in absence of extinction training. Together with
the theoretical model based on preclinical findings discussed
above,9 these preliminary human treatment studies suggest
that cannabinoid pharmacotherapy may serve a broader goal
of improving adaption of fear responses, without being
specific to exposure training. Cannabinoid-based pharma-
cotherapy for anxiety disorder could potentially be greatly
facilitated by additional studies of the specific fear- and
anxiety-related processes that may be affected by existent
pharmacological agents and the development of more
selective agents, as CB1 agonists appear to have rather
diffuse effects.
In conclusion, the present study provides one of the first
attempts of translating preclinical evidence regarding the
involvement of the ECS in fear extinction to humans. Our data
suggest that endocannabinoid signaling is involved in regula-
tion of the basic defensive state when previously acquired fear
is no longer adaptive. Human CB1 functioning may hence
modulate maintenance of fear responses, which supports the
possibility of novel treatments of human anxiety by targeting
this receptor. However, further development of cannabinoid-
dependent pharmacological treatments for anxiety must await
additional experimental and pharmacological research. Mole-
cular evidence that rs2180619 indeed modulates CB1
expression may provide the missing link to conclude that
CB1 is a promising target for the treatment of anxiety in
humans. This may provide an important breakthrough given
the high prevalence of anxiety disorders71 and the limited
efficacy of current treatments.72–75
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